 | • レポートコード：MRC2-11QY13581 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は成人用悪性神経膠腫治療薬のグローバル市場について調査・分析したレポートです。種類別（化学療法、標的薬物療法、放射線療法）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別成人用悪性神経膠腫治療薬の競争状況、市場シェア ・世界の成人用悪性神経膠腫治療薬市場：種類別市場規模 2015年-2020年（化学療法、標的薬物療法、放射線療法） ・世界の成人用悪性神経膠腫治療薬市場：種類別市場規模予測 2021年-2026年（化学療法、標的薬物療法、放射線療法） ・世界の成人用悪性神経膠腫治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の成人用悪性神経膠腫治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の成人用悪性神経膠腫治療薬市場分析：米国、カナダ ・ヨーロッパの成人用悪性神経膠腫治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの成人用悪性神経膠腫治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の成人用悪性神経膠腫治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの成人用悪性神経膠腫治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Merck、Roche、Arbor Pharmaceuticals、Pfizer、AbbVie、Amgen、Bristol-Myers Squibb、Sun Pharmaceuticals、Teva Pharmaceutical、Emcure Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pipeline.
In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme, which accounts for 12% to 15% of all intracranial tumors and 50% to 60% of all astrocytic tumors, is likely to be the most attractive segment during the forecast period, followed by anaplastic astrocytoma.
Market Analysis and Insights: Global Adult Malignant Glioma Therapeutics Market
The global Adult Malignant Glioma Therapeutics market size is projected to reach US$ 1332.1 million by 2026, from US$ 1261 million in 2020, at a CAGR of 5.2%% during 2021-2026.
Global Adult Malignant Glioma Therapeutics Scope and Market Size
Adult Malignant Glioma Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Adult Malignant Glioma Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Merck
Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceuticals
Teva Pharmaceutical
Emcure Pharmaceuticals
Market segment by Type, the product can be split into
Chemotherapy
Targeted Drug Therapy
Radiation Therapy
Market segment by Application, split into
Hospitals
Clinics
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Adult Malignant Glioma Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Adult Malignant Glioma Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Targeted Drug Therapy
1.4.4 Radiation Therapy
1.5 Market by Application
1.5.1 Global Adult Malignant Glioma Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Adult Malignant Glioma Therapeutics Market Perspective (2015-2026)
2.2 Global Adult Malignant Glioma Therapeutics Growth Trends by Regions
2.2.1 Adult Malignant Glioma Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Adult Malignant Glioma Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Adult Malignant Glioma Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Adult Malignant Glioma Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Adult Malignant Glioma Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Adult Malignant Glioma Therapeutics Players by Market Size
3.1.1 Global Top Adult Malignant Glioma Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Adult Malignant Glioma Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Adult Malignant Glioma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Adult Malignant Glioma Therapeutics Market Concentration Ratio
3.2.1 Global Adult Malignant Glioma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Adult Malignant Glioma Therapeutics Revenue in 2019
3.3 Adult Malignant Glioma Therapeutics Key Players Head office and Area Served
3.4 Key Players Adult Malignant Glioma Therapeutics Product Solution and Service
3.5 Date of Enter into Adult Malignant Glioma Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Adult Malignant Glioma Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020)
5.2 Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Adult Malignant Glioma Therapeutics Market Size (2015-2020)
6.2 Adult Malignant Glioma Therapeutics Key Players in North America (2019-2020)
6.3 North America Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020)
6.4 North America Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Adult Malignant Glioma Therapeutics Market Size (2015-2020)
7.2 Adult Malignant Glioma Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020)
7.4 Europe Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Adult Malignant Glioma Therapeutics Market Size (2015-2020)
8.2 Adult Malignant Glioma Therapeutics Key Players in China (2019-2020)
8.3 China Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020)
8.4 China Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Adult Malignant Glioma Therapeutics Market Size (2015-2020)
9.2 Adult Malignant Glioma Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020)
9.4 Japan Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Adult Malignant Glioma Therapeutics Market Size (2015-2020)
10.2 Adult Malignant Glioma Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Adult Malignant Glioma Therapeutics Market Size (2015-2020)
11.2 Adult Malignant Glioma Therapeutics Key Players in India (2019-2020)
11.3 India Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020)
11.4 India Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Adult Malignant Glioma Therapeutics Market Size (2015-2020)
12.2 Adult Malignant Glioma Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Merck
13.1.1 Merck Company Details
13.1.2 Merck Business Overview
13.1.3 Merck Adult Malignant Glioma Therapeutics Introduction
13.1.4 Merck Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020))
13.1.5 Merck Recent Development
13.2 Roche
13.2.1 Roche Company Details
13.2.2 Roche Business Overview
13.2.3 Roche Adult Malignant Glioma Therapeutics Introduction
13.2.4 Roche Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020)
13.2.5 Roche Recent Development
13.3 Arbor Pharmaceuticals
13.3.1 Arbor Pharmaceuticals Company Details
13.3.2 Arbor Pharmaceuticals Business Overview
13.3.3 Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Introduction
13.3.4 Arbor Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020)
13.3.5 Arbor Pharmaceuticals Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer Adult Malignant Glioma Therapeutics Introduction
13.4.4 Pfizer Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 AbbVie
13.5.1 AbbVie Company Details
13.5.2 AbbVie Business Overview
13.5.3 AbbVie Adult Malignant Glioma Therapeutics Introduction
13.5.4 AbbVie Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020)
13.5.5 AbbVie Recent Development
13.6 Amgen
13.6.1 Amgen Company Details
13.6.2 Amgen Business Overview
13.6.3 Amgen Adult Malignant Glioma Therapeutics Introduction
13.6.4 Amgen Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020)
13.6.5 Amgen Recent Development
13.7 Bristol-Myers Squibb
13.7.1 Bristol-Myers Squibb Company Details
13.7.2 Bristol-Myers Squibb Business Overview
13.7.3 Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Introduction
13.7.4 Bristol-Myers Squibb Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020)
13.7.5 Bristol-Myers Squibb Recent Development
13.8 Sun Pharmaceuticals
13.8.1 Sun Pharmaceuticals Company Details
13.8.2 Sun Pharmaceuticals Business Overview
13.8.3 Sun Pharmaceuticals Adult Malignant Glioma Therapeutics Introduction
13.8.4 Sun Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020)
13.8.5 Sun Pharmaceuticals Recent Development
13.9 Teva Pharmaceutical
13.9.1 Teva Pharmaceutical Company Details
13.9.2 Teva Pharmaceutical Business Overview
13.9.3 Teva Pharmaceutical Adult Malignant Glioma Therapeutics Introduction
13.9.4 Teva Pharmaceutical Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020)
13.9.5 Teva Pharmaceutical Recent Development
13.10 Emcure Pharmaceuticals
13.10.1 Emcure Pharmaceuticals Company Details
13.10.2 Emcure Pharmaceuticals Business Overview
13.10.3 Emcure Pharmaceuticals Adult Malignant Glioma Therapeutics Introduction
13.10.4 Emcure Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020)
13.10.5 Emcure Pharmaceuticals Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Adult Malignant Glioma Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Adult Malignant Glioma Therapeutics Revenue
Table 3. Ranking of Global Top Adult Malignant Glioma Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Adult Malignant Glioma Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Targeted Drug Therapy
Table 7. Key Players of Radiation Therapy
Table 8. Global Adult Malignant Glioma Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Adult Malignant Glioma Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Adult Malignant Glioma Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Adult Malignant Glioma Therapeutics Market Share by Regions (2015-2020)
Table 12. Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Adult Malignant Glioma Therapeutics Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Adult Malignant Glioma Therapeutics Market Growth Strategy
Table 18. Main Points Interviewed from Key Adult Malignant Glioma Therapeutics Players
Table 19. Global Adult Malignant Glioma Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 20. Global Adult Malignant Glioma Therapeutics Market Share by Players (2015-2020)
Table 21. Global Top Adult Malignant Glioma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adult Malignant Glioma Therapeutics as of 2019)
Table 22. Global Adult Malignant Glioma Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Adult Malignant Glioma Therapeutics Product Solution and Service
Table 25. Date of Enter into Adult Malignant Glioma Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 28. Global Adult Malignant Glioma Therapeutics Market Size Share by Type (2015-2020)
Table 29. Global Adult Malignant Glioma Therapeutics Revenue Market Share by Type (2021-2026)
Table 30. Global Adult Malignant Glioma Therapeutics Market Size Share by Application (2015-2020)
Table 31. Global Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 32. Global Adult Malignant Glioma Therapeutics Market Size Share by Application (2021-2026)
Table 33. North America Key Players Adult Malignant Glioma Therapeutics Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Adult Malignant Glioma Therapeutics Market Share (2019-2020)
Table 35. North America Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 36. North America Adult Malignant Glioma Therapeutics Market Share by Type (2015-2020)
Table 37. North America Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 38. North America Adult Malignant Glioma Therapeutics Market Share by Application (2015-2020)
Table 39. Europe Key Players Adult Malignant Glioma Therapeutics Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Adult Malignant Glioma Therapeutics Market Share (2019-2020)
Table 41. Europe Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Adult Malignant Glioma Therapeutics Market Share by Type (2015-2020)
Table 43. Europe Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Adult Malignant Glioma Therapeutics Market Share by Application (2015-2020)
Table 45. China Key Players Adult Malignant Glioma Therapeutics Revenue (2019-2020) (Million US$)
Table 46. China Key Players Adult Malignant Glioma Therapeutics Market Share (2019-2020)
Table 47. China Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 48. China Adult Malignant Glioma Therapeutics Market Share by Type (2015-2020)
Table 49. China Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 50. China Adult Malignant Glioma Therapeutics Market Share by Application (2015-2020)
Table 51. Japan Key Players Adult Malignant Glioma Therapeutics Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Adult Malignant Glioma Therapeutics Market Share (2019-2020)
Table 53. Japan Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Adult Malignant Glioma Therapeutics Market Share by Type (2015-2020)
Table 55. Japan Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Adult Malignant Glioma Therapeutics Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Adult Malignant Glioma Therapeutics Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Adult Malignant Glioma Therapeutics Market Share (2019-2020)
Table 59. Southeast Asia Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Adult Malignant Glioma Therapeutics Market Share by Type (2015-2020)
Table 61. Southeast Asia Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Adult Malignant Glioma Therapeutics Market Share by Application (2015-2020)
Table 63. India Key Players Adult Malignant Glioma Therapeutics Revenue (2019-2020) (Million US$)
Table 64. India Key Players Adult Malignant Glioma Therapeutics Market Share (2019-2020)
Table 65. India Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 66. India Adult Malignant Glioma Therapeutics Market Share by Type (2015-2020)
Table 67. India Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 68. India Adult Malignant Glioma Therapeutics Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Adult Malignant Glioma Therapeutics Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Adult Malignant Glioma Therapeutics Market Share (2019-2020)
Table 71. Central & South America Adult Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Adult Malignant Glioma Therapeutics Market Share by Type (2015-2020)
Table 73. Central & South America Adult Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Adult Malignant Glioma Therapeutics Market Share by Application (2015-2020)
Table 75. Merck Company Details
Table 76. Merck Business Overview
Table 77. Merck Product
Table 78. Merck Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 79. Merck Recent Development
Table 80. Roche Company Details
Table 81. Roche Business Overview
Table 82. Roche Product
Table 83. Roche Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 84. Roche Recent Development
Table 85. Arbor Pharmaceuticals Company Details
Table 86. Arbor Pharmaceuticals Business Overview
Table 87. Arbor Pharmaceuticals Product
Table 88. Arbor Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 89. Arbor Pharmaceuticals Recent Development
Table 90. Pfizer Company Details
Table 91. Pfizer Business Overview
Table 92. Pfizer Product
Table 93. Pfizer Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 94. Pfizer Recent Development
Table 95. AbbVie Company Details
Table 96. AbbVie Business Overview
Table 97. AbbVie Product
Table 98. AbbVie Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 99. AbbVie Recent Development
Table 100. Amgen Company Details
Table 101. Amgen Business Overview
Table 102. Amgen Product
Table 103. Amgen Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 104. Amgen Recent Development
Table 105. Bristol-Myers Squibb Company Details
Table 106. Bristol-Myers Squibb Business Overview
Table 107. Bristol-Myers Squibb Product
Table 108. Bristol-Myers Squibb Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 109. Bristol-Myers Squibb Recent Development
Table 110. Sun Pharmaceuticals Business Overview
Table 111. Sun Pharmaceuticals Product
Table 112. Sun Pharmaceuticals Company Details
Table 113. Sun Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 114. Sun Pharmaceuticals Recent Development
Table 115. Teva Pharmaceutical Company Details
Table 116. Teva Pharmaceutical Business Overview
Table 117. Teva Pharmaceutical Product
Table 118. Teva Pharmaceutical Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 119. Teva Pharmaceutical Recent Development
Table 120. Emcure Pharmaceuticals Company Details
Table 121. Emcure Pharmaceuticals Business Overview
Table 122. Emcure Pharmaceuticals Product
Table 123. Emcure Pharmaceuticals Revenue in Adult Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 124. Emcure Pharmaceuticals Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Adult Malignant Glioma Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Targeted Drug Therapy Features
Figure 4. Radiation Therapy Features
Figure 5. Global Adult Malignant Glioma Therapeutics Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Adult Malignant Glioma Therapeutics Report Years Considered
Figure 10. Global Adult Malignant Glioma Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Adult Malignant Glioma Therapeutics Market Share by Regions: 2020 VS 2026
Figure 12. Global Adult Malignant Glioma Therapeutics Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Adult Malignant Glioma Therapeutics Market Share by Players in 2019
Figure 15. Global Top Adult Malignant Glioma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adult Malignant Glioma Therapeutics as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Adult Malignant Glioma Therapeutics Revenue in 2019
Figure 17. North America Adult Malignant Glioma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Adult Malignant Glioma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Adult Malignant Glioma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Adult Malignant Glioma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Adult Malignant Glioma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Adult Malignant Glioma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Adult Malignant Glioma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
悪性神経膠腫の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…- 悪性神経膠腫治療の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- 悪性神経膠腫治療薬の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- ポンチングリオーマ治療薬の世界市場（～2026年） Market Analysis and Insights: Global Pontine Glioma Drug Market The global Pontine Glioma Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Pontine Glioma Drug Scope and Market Size Pontine Glioma Drug market is seg…
- 成人T細胞白血病/リンパ腫治療の世界市場（～2026年） Adult T-cell lymphoma/leukemia (ATL) is a rare T-cell lymphoproliferative neoplasm caused by human T-lymphotrophic virus 1. In its more common, aggressive forms, ATL carries one of the poorest prognoses of the non-Hodgkin lymphomas. The disease has clinical subtypes (ie, acute, lymphoma, chronic, an…